<- Go Home
Vascular Biogenics Ltd.
As of October 16, 2023, Vascular Biogenics Ltd. was acquired by Notable Labs, Inc., in a reverse merger transaction. Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi’in, Israel.
Market Cap
$12.1M
Volume
56.4K
Cash and Equivalents
$20.8M
EBITDA
-$7.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$46.0K
Profit Margin
N/A
52 Week High
$11.20
52 Week Low
$3.53
Dividend
N/A
Price / Book Value
0.66
Price / Earnings
-1.55
Price / Tangible Book Value
0.66
Enterprise Value
-$8.7M
Enterprise Value / EBITDA
1.17
Operating Income
-$8.2M
Return on Equity
35.98%
Return on Assets
-18.12
Cash and Short Term Investments
$20.8M
Debt
N/A
Equity
$18.3M
Revenue
N/A
Unlevered FCF
-$10.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium